Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Nov 10, 2009

Premium

Rosetta Genomics has appointed Kenneth Berlin as president and CEO. Berlin will also serve on the company’s board of directors. Since 2007 Berlin has been worldwide general manager at cellular and molecular cancer diagnostics company Veridex.


Nanosphere said last week that Chief Technology Officer and Vice President of R&D William Cork has resigned from his positions to pursue other opportunities, and that his duties will be reassigned.


WaferGen Biosystems has appointed Christopher Sears to its scientific advisory board. Sears is chief scientific officer at Ambergen, and he has worked as an academic oncologist at Children’s Hospital Boston, The Broad Institute, Harvard Medical School, and Dana Farber Cancer Institute. Sears also has been a scientific adviser to Genzyme Genetics, Myriad Genetics, and Invitrogen.


Sequenom has appointed Paul Maier to begin serving as its interim chief financial officer. He has worked as senior vice president and CFO of Ligand Pharmaceuticals, where he helped build the company from its venture stage through raising more than $1 billion in equity and debt financings. He also worked at ICN Pharmaceuticals for six years in various management and finance positions.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.